Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Colorcon
Moodys
Harvard Business School
AstraZeneca

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,561,197


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,561,197 protect, and when does it expire?

Patent 9,561,197 protects RAVICTI and is included in one NDA.

This patent has thirty-five patent family members in twenty-three countries.

Summary for Patent: 9,561,197
Title:Methods of therapeutic monitoring of phenylacetic acid prodrugs
Abstract: The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.
Inventor(s): Scharschmidt; Bruce (San Francisco, CA), Mokhtarani; Masoud (Walnut Creek, CA)
Assignee: Horizon Therapeutics, LLC (Lake Forest, IL)
Application Number:13/610,580
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,561,197
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,561,197

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Horizon Therap RAVICTI glycerol phenylbutyrate LIQUID;ORAL 203284-001 Feb 1, 2013 RX Yes Yes   Start Trial   Start Trial DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,561,197

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2012377389   Start Trial
Australia 2018200163   Start Trial
Australia 2019201811   Start Trial
Brazil 112014026138   Start Trial
Chile 2014002807   Start Trial
Chile 2017001375   Start Trial
China 104540507   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKinsey
Johnson and Johnson
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.